AC
ESPR icon

AXQ Capital’s Esperion Therapeutics ESPR Stock Holding History

AXQ Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157K Sell
49,712
-44,447
-47% -$124K 0.02% 754
2026
Q1 		$258K Buy
+94,159
New +$298K 0.03% 645
2025
Q4 		– Sell
-38,930
Closed -$103K – 789
2025
Q3 		$103K Buy
+38,930
New +$75.3K 0.04% 515
2023
Q1 		– Sell
-48,061
Closed -$299K – 521
2022
Q4 		$299K Buy
+48,061
New +$344K 0.21% 187

Other funds holding ESPR

Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Arbitrage
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

AXQ Capital's ESPR Position: Q2 2026 in Review

AXQ Capital reduced its Esperion Therapeutics (ESPR) stake by 47% in Q2 2026, selling an estimated $124K and leaving 49,712 shares worth $157K. The position accounts for 0.02% of the portfolio, ranked #754.

AXQ Capital first reported a position in ESPR in Q4 2022 and has held it in 4 quarters since. The position peaked at $299K in Q4 2022. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • AXQ Capital held 49,712 shares of Esperion Therapeutics worth $157K as of Q2 2026.
  • AXQ Capital sold 44,447 Esperion Therapeutics shares in Q2 2026, an estimated $124K.
  • Esperion Therapeutics made up 0.02% of AXQ Capital's portfolio in Q2 2026, its #754 holding.
  • AXQ Capital first reported a position in Esperion Therapeutics in Q4 2022 and has held it in 4 quarters since.
  • AXQ Capital's Esperion Therapeutics position peaked at $299K in Q4 2022.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.